There are no big surprises in the Q2’21 financials of Asarina Pharma. After the disappointing phase 2a readout for sepranolone in menstrual migraine, we now shift our focus to Tourette’s.
ANNONS
There are no big surprises in the Q2’21 financials of Asarina Pharma. After the disappointing phase 2a readout for sepranolone in menstrual migraine, we now shift our focus to Tourette’s.